NORWALK, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock and warrants to purchase 2,500,000 shares of common stock (collectively, the “Securities”). Each share of common stock and accompanying warrant to purchase one share of common stock are being sold together at a co ...

Core Viewpoint - Protara Therapeutics, Inc. has announced a public offering of 13,043,479 shares of common stock priced at $5.75 per share, aiming to raise approximately $75 million for clinical development and other corporate purposes [1]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,956,521 shares at the public offering price [1]. - The offering is expected to close on December 8, 2025, pending customary closing conditions [1]. - Protara intends to use the net proceeds for the clinical development of TARA-002 and other clinical programs, as well as for working capital and general corporate purposes [1]. Group 2: Underwriters and Management - J.P. Morgan, TD Cowen, and Piper Sandler are acting as joint book-running managers for the offering [2]. - LifeSci Capital is serving as the lead manager, while H.C. Wainwright & Co. is acting as a manager of the offering [2]. Group 3: Regulatory Information - The shares will be issued under an effective shelf registration statement on Form S-3, declared effective on November 14, 2023, by the U.S. Securities and Exchange Commission [3]. - A final prospectus supplement will be filed with the SEC and will be available on their website [3].

Core Viewpoint - Miata Metals Corp. is conducting a public offering of common shares at a price of $0.48 per share, aiming to raise up to $10,000,080, with the potential for total gross proceeds of $11,500,080 if the over-allotment option is fully exercised [1][2]. Group 1: Offering Details - The offering is being managed by a syndicate of agents led by Cormark Securities Inc., which has been granted an over-allotment option to sell an additional 3,125,000 common shares [2]. - The closing of the offering is anticipated to occur around December 8, 2025, pending regulatory approval [4]. Group 2: Company Information - Miata Metals Corp. is a Canadian mineral exploration company listed on the Canadian Securities Exchange, OTCQB, and Frankfurt Exchanges, focusing on the acquisition, exploration, and development of mineral properties [6]. - The company holds a 70% interest in the Sela Creek Gold Project, covering approximately 215 km², and a 70% beneficial interest in the Nassau Gold Project in Suriname, both of which are located in the greenstone belt of Suriname [6].

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of $75 million in aggregate of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants t ...

https://t.co/Yber9So4ea is set to begin trading Wednesday morning in Singapore’s biggest initial public offering since 2017 excluding real estate investment trusts https://t.co/dPLXe0IOSB ...

Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of ne ...

Company News - First Digital Group (FDUSD issuer) plans to go public via merger with CSLM Digital Asset Acquisition Corp III [1]

KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced an underwritten public offering of 5,500,000 common shares. Kestra is offering these shares pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (“SEC”). Kestra also intends to grant the underwriters a 30-day option to purchase up to an additional 825,000 common shares at the public offerin ...

Core Viewpoint - Pasithea Therapeutics Corp. has announced a public offering of 80 million shares at $0.75 per share, aiming to raise approximately $60 million to support its ongoing research and development efforts [1][3]. Group 1: Offering Details - The public offering consists of 80,000,000 shares of common stock or pre-funded warrants at an offering price of $0.75 per share [1]. - The offering is led by healthcare-focused investors, including Vivo Capital, Janus Henderson Investors, and others [1][8]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Group 2: Financial Implications - The gross proceeds from the offering are expected to be around $60 million before deducting fees and expenses [3]. - The net proceeds will be used for general corporate purposes, including ongoing research, clinical trials, and potential acquisitions [3]. - Following the offering, the company's cash runway is projected to extend through at least the first half of 2028 [3][8]. Group 3: Company Overview - Pasithea is a clinical-stage biotechnology company focused on developing PAS-004, a macrocyclic MEK inhibitor for treating neurofibromatosis type 1-associated plexiform neurofibromas [6]. - The company is currently conducting a Phase 1 clinical trial for PAS-004 in advanced cancer patients and a Phase 1/1b trial in adult patients with NF1-associated plexiform neurofibromas [6].

Core Viewpoint - Shares of Fannie Mae experienced significant volatility last week, influenced by investor Bill Ackman's presentation, which did not provide clarity on the anticipated public offering [1] Group 1 - Fannie Mae's stock performance has been erratic, reflecting uncertainty in the market regarding its future [1] - Bill Ackman, a prominent investor, presented insights that failed to alleviate concerns about the planned public offering [1]